Good afternoon, ladies and gentlemen. Welcome to the 2026 Annual Meeting of Stockholders of Interpace Biosciences. The meeting is being held virtually. My name is Thomas Burnell. I am chairman of the board of directors, as well as the President and Chief Executive Officer of the company. I will act as chairman of the meeting. Joining me today is Chris McCarthy, the company's Chief Financial and Chief Operating Officer. I would also like to introduce the following board members who are on our call with us today, Dr. Vijay Aggarwal and Dr. Joseph Keegan. I would like to also introduce Merrill Kraines of McDermott Will & Schulte, our outside legal counsel, and Patrick Boyle of EisnerAmper LLP, the company's independent registered public accounting firm. Both myself and Mr. Boyle will be available to answer questions at the end of this meeting. Peter Deskovich, a representative of Broadridge Financial Solutions, will serve as the inspector of elections for this meeting, with authority, among other things, to receive and determine the validity of all proxies and ballots submitted and to certify the number of shares of common stock represented at this meeting, as well as the results of the vote of the company stockholders on any proposal. I will now call upon Chris McCarthy to present proof of the due calling of this meeting of stockholders. Mr. Chairman, I present the affidavit of a representative of Broadridge confirming that the notice regarding the internet availability of proxy materials for the annual meeting, as well as the notice of the meeting, proxy statement, and form of proxy, was mailed on or about July 10th, 2026, to all stockholders of Interpace Biosciences of record as of June 29th, 2026, the record date for this meeting. Unless specifically requested, we will dispense with the reading of such notice. A certified list of the stockholders entitled to vote at the meeting is available and may be inspected by any stockholder. Additional copies of the proxy statement are also available. Thank you, Chris. I direct that the affidavit of mailing be filed with the minutes of this meeting. I present the oath of office, sworn and signed by Mr. Deskovich as the inspector of election, and direct that the oath also be filed with the minutes. The inspector has advised that he has tallied the number of votes represented in person or by proxy at the meeting, and that the holders of 26,578,494 shares of common stock are represented at this meeting, the shares of which represent approximately 95.94% of the shares entitled to vote at the meeting. A quorum is therefore present, and the meeting can now proceed to the consideration of the matters set forth in the notice of meeting. Since no stockholder approvals or proposals were filed in advance of this meeting, the business of the meeting is limited to the matters contained in the notice of meeting, which are as follows. Proposal one, approval of an amended and restated certificate of incorporation. Proposal two, grant to the company's board of directors discretionary authority to amend the company's certificate of incorporation to effect a reverse stock split of the company's common stock within the range of one for two one for 10, with the exact ratio, if any, to be determined by the board not later than one year after stockholder approval thereof. Proposal three, approval of the company's 2026 equity incentive plan. Proposal four, approval of the company's 2026 employee stock purchase plan. Proposal five, if the stockholders approve Proposal one to amend and restate the company's certificate of incorporation, the election of five directors to serve on the board of directors for a term ending as of our 2027 annual meeting, or until such director's successor is duly elected and qualified. If the stockholders do not approve Proposal one to amend and restate the company's certificate of incorporation, the election of two directors to serve as Class 1 directors for a term ending as of our 2028 annual meeting of stockholders and two directors to serve as Class 3 directors for a term ending as of our 2029 annual meeting of stockholders, or until each such director's successor is duly elected and qualified. Proposal six, approval of a non-binding advisory vote on the resolution approving the compensation of our named executive officers. Proposal seven, ratification of the appointment of EisnerAmper LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. Will all those who intend to vote electronically at this meeting but have not done so, please do so now. The polls are now closed with respect to the proposals. Mr. Chairman, the inspector has given me his report on the proposals presented at this meeting. I would like to advise the meeting that with respect to the proposals, Tom Burnell and I, as appointed in the official proxy card, have voted in accordance with the proxies received from stockholders. Mr. Deskovich, would you please report on the votes taken with respect to proposal number 1, the approval of an amended and restated certificate of incorporation? Mr. Chairman, I would like to advise the meeting that with respect to proposal number 1, 24,981,181 votes have been cast in favor of the proposal, 246,552 votes have been cast against the proposal, and 3,625 votes have abstained. With respect to proposal number 1, more than 75% of the shares of common stock outstanding as of the record date has been cast in favor of the proposal. Therefore, proposal number 1 is approved. Mr. Deskovich, would you please report on the vote taken with respect to proposal number 2, the grant of discretionary authority to the board of directors to effect a reverse stock split? Mr. Chairman, I would like to advise the meeting that with respect to proposal number 2, 26,180,980 votes have been cast in favor of the proposal, and 397,262 votes have been cast against the proposal, and 252 votes have abstained. With respect to proposal number 2, the votes cast for the proposal exceed the votes cast against the proposal. Therefore, proposal number 2 is approved. Mr. Deskovich, would you please report on the vote taken with respect to proposal number 3, the approval of the 2026 equity incentive plan? I would like to advise the meeting that with respect to proposal number three, 24,887,762 votes have been cast in favor of the proposal, 339,193 votes have been cast against the proposal, and 4,403 votes have abstained. With respect to proposal number 3, a majority of the votes cast at the meeting have voted for the proposal. Thank you. Proposal number 3 is approved. Mr. Deskovich, would you please report on the votes taken with respect to proposal number 4, the approval of the employee stock purchase plan? I would like to advise the meeting that with respect to proposal number 4, 24,580,773 votes have been cast in favor of the proposal, 648,533 votes have been cast against the proposal, and 2,052 votes have abstained. With respect to proposal number 4, a majority of the votes cast at the meeting have voted for the proposal. Thank you. Proposal number 4 is approved. We will now pause to hear from counsel that the amended and restated certificate of incorporation providing for a declassified board, amongst other things, has been filed with Delaware. Thank you, Tom Burnell. I think we need another minute. Crystal, can you confirm? Confirmed. We need one minute. Okay. I appreciate everyone's patience. We are filed. Okay, thank you. Thank you for confirming. Mr. Deskovich, would you please report on the vote taken with respect to proposal number 5, the election of directors? Since proposal number 1 was approved, resulting in the declassification of the board, 5 director nominees are to be elected and unclassified directors to hold a term of office until the company's 2027 annual meeting of stockholders, or until their successors are duly elected and qualified. The five nominees who received a plurality of the votes cast are Dr. Vijay Aggarwal, Thomas Burnell, Dr. Joseph Keegan, Fortunato Ron Rocca, and Stephen J. Sullivan. Aggarwal, Burnell, Keegan, Rocca, and Sullivan have each been elected as directors for one-year terms. Mr. Deskovich, would you please report on the vote taken with respect to proposal number 6, the non-binding advisory vote approving the compensation of our named executive officers? I would like to advise the meeting that with respect to proposal number 6, 24,952,970 votes have been cast in favor of the proposal. 249,460 votes have been cast against the proposal, and 28,928 votes have abstained. With respect to proposal number 6, a majority of votes cast at the meeting have voted for the proposal. Thank you. Proposal number 6 is approved. Mr. Deskovich, would you please report on the vote taken with respect to proposal number 7, ratification of the appointment of EisnerAmper LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. I would like to advise the meeting that with respect to proposal number 7, 26,442,760 votes have been cast in favor of the proposal. 134,660 votes have been cast against the proposal, and 1,074 votes have abstained. With respect to proposal number 7, a majority of the votes cast at the meeting have voted for the proposal. Proposal number 7 is approved. Before answering questions, the chair will now entertain a motion for the adjournment of the meeting. I will make that motion. Is there a second? Yes. Second. All those in favor of the motion, please signify their assent by saying aye. Aye. All those opposed to the motion, please signify their dissent by saying nay. Thank you for listening. The meeting is formally adjourned. Thank you for listening through the legal formalities of the meetings. I know now there are a couple of questions that have been sent in that I would like to address at this time. The first one is related to specifically the strategic priorities for the company over the next 12-18 months, and specifically, how does the product portfolio change as a result of that? The third part of that question is, do we intend to expand research again to expand the product line? The last part of that question really all ties together. The company, in its most recent press release, indicated that it is our intention to bring back a new and improved, if you will, pancreatic test for the diagnostics risk stratification of pancreatic cancer. We also have an expectation to continue to look for opportunities that would expand the product portfolio, either through licensing new technologies or acquiring new technologies that are ancillary to or complementary to our current portfolio. We have, in fact, and do in fact intend to rebuild our research effort. We have hired a chief scientific officer who will be starting with the company on September 8th, and it will be his responsibility to help build out that strategic plan for the research that the company tends to do. By research, we mean research that is focused strictly on the commercial development of high-value tests that are complementary to our current testing portfolio. The part of that question is how do we intend to use cash now that the company's cash flow positive? That is one of the areas where we're focusing on in terms of utilization of cash, and that's product development. The other is we continue to invest in automation and efficiency in our lab to help reduce turnaround time and obtain quicker results for our physicians. Unfortunately, I'm not able to answer the next question related to the strategic activities and actions that are required for the Nasdaq uplist. We're not in a position where that can be discussed because there has not been a formal approval by the board for the reverse stock split. Are there other questions?